ALS is fatal, but the timeline and how it progresses varies significantly between people

ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that is currently fatal. There is no cure. The disease damages motor neurons—the nerve cells that control voluntary muscles—and as those neurons die, the muscles they control weaken and eventually stop working. Eventually, the muscles that control breathing fail, and without mechanical ventilation, a person cannot survive.

However, "fatal" does not mean "immediate." Some people live two to three years after diagnosis. Others live ten years or longer. A small number of people with ALS experience slower progression, and a few have had periods where the disease appears to stabilize, though this is rare. The variation is real and significant enough that doctors cannot predict with certainty how long any individual will live.

Key Takeaways

  • ALS damages motor neurons and progressively weakens muscles, including those needed for breathing, and there is currently no cure.
  • Most people with ALS live two to five years after diagnosis, but some live considerably longer, and the rate of progression varies widely.
  • Mechanical ventilation can extend life when breathing muscles fail, but this is a decision each person makes based on their own values.
  • Palliative care and symptom management can improve quality of life throughout the disease course, regardless of prognosis.
  • Research into treatments that slow progression is ongoing, and a small number of drugs have shown modest effects in slowing decline.

How ALS damages the body over time

ALS begins when motor neurons in the brain and spinal cord start to degenerate. Early symptoms often appear in one region—the hands, feet, or speech—and spread from there. A person might notice their grip weakening, their legs becoming stiff, or their speech becoming slurred. As more motor neurons die, weakness spreads to other muscles.

The disease does not affect sensation, cognition, or the ability to think clearly. A person with ALS typically remains mentally sharp throughout the illness. This is one of the cruelest aspects of the disease: the mind remains intact while the body fails.

As the disease progresses, weakness eventually reaches the diaphragm—the muscle that controls breathing. When the diaphragm weakens enough, a person cannot breathe on their own. At this point, mechanical ventilation becomes necessary to stay alive. Without it, respiratory failure is fatal.

Why survival time varies so much between people

Doctors do not fully understand why some people with ALS progress slowly and others rapidly. Age at diagnosis matters somewhat—people diagnosed younger sometimes live longer, though this is not a reliable rule. The part of the body where ALS starts also influences speed: people whose disease begins in the legs sometimes progress more slowly than those whose disease starts with speech or swallowing.

Genetics play a role. About 10 percent of ALS cases run in families (familial ALS), and some genetic mutations are associated with slower or faster progression. Most ALS cases appear sporadic, with no family history, and the genetic factors in those cases are still being studied.

Overall health, age, and how quickly someone receives diagnosis and begins treatment also matter. Starting treatment earlier may slow decline slightly. But none of these factors reliably predict an individual's course. Two people diagnosed on the same day with the same genetic mutation can have very different trajectories.

What treatments can slow progression

Riluzole is an FDA-approved drug that has been used for ALS since 1995. It extends median survival by a few months—roughly two to three months on average. It works by reducing glutamate, a chemical that damages motor neurons. Riluzole does not stop ALS or reverse damage; it slows the rate of decline.

Edaravone is a newer drug approved in 2017. In clinical trials, it slowed decline by roughly 33 percent over a six-month period in people with early-stage ALS. Like riluzole, it does not cure the disease or restore lost function. Both drugs work best when started early in the disease course.

Other drugs are in development and clinical trials. Research continues into approaches targeting different mechanisms of motor neuron death. But as of now, no treatment stops ALS entirely or reverses the damage already done. The goal of current treatment is to slow progression and manage symptoms.

The role of mechanical ventilation in extending life

When ALS reaches the diaphragm, a person faces a decision about mechanical ventilation. A ventilator is a machine that pushes air into the lungs through a tube. With a ventilator, a person can continue living even when their own breathing muscles no longer work. Some people with ALS use ventilators for years.

Choosing ventilation is a deeply personal decision. It extends life but does not reverse the disease. A person on a ventilator remains paralyzed and cannot speak (though they can communicate through eye-tracking devices or other assistive technology). They require 24-hour care. Some people find this acceptable and meaningful; others do not.

Not everyone with ALS chooses ventilation. Some decide that when breathing becomes difficult, they will pursue comfort-focused care instead. This is a valid choice, and palliative care teams support people in either direction. The decision belongs entirely to the person with ALS and their family.

Palliative care and quality of life

Palliative care is medical care focused on comfort and quality of life rather than cure. For ALS, it includes managing pain, difficulty swallowing, constipation, sleep problems, and emotional distress. These symptoms can be treated even when the underlying disease cannot be cured.

Speech-language pathologists help people adapt communication as speech becomes difficult. Occupational therapists suggest adaptive equipment—devices that make daily tasks possible as strength declines. Nutritionists address swallowing problems. Mental health support addresses depression and anxiety, which are common in ALS.

Palliative care is not the same as giving up. It is active, skilled medical care aimed at living as well as possible with a serious illness. Many people with ALS receive both disease-modifying treatment (like riluzole) and palliative care at the same time.

Research into future treatments

ALS research is active across multiple approaches. Scientists are studying gene therapy, stem cell therapy, and drugs that target different pathways of motor neuron death. Some trials are testing whether certain drugs used for other diseases might slow ALS. Others are investigating whether earlier, more aggressive treatment might change outcomes.

Progress has been slow compared to some other diseases, partly because ALS is rare and partly because the underlying biology is complex. But the field is moving. The drugs available today did not exist twenty years ago. It is possible that treatments available in five or ten years will be more effective than current options.

Clinical trials for ALS are ongoing. People interested in participating can search ClinicalTrials.gov or ask their neurologist about trials recruiting in their area. Participation in research contributes to the knowledge base that may help future patients.

Frequently Asked Questions

How long do most people live after an ALS diagnosis?

The median survival is two to five years from diagnosis, meaning half of people live longer and half shorter. However, this is an average. Some people live one year or less; others live ten years or more. Your doctor cannot predict your individual timeline based on population averages.

Can ALS go into remission or stop progressing?

True remission is extremely rare in ALS. A very small number of people experience periods where progression slows dramatically or appears to pause, but this is not the same as remission. The disease typically continues to progress, though at different rates in different people.

Is there any chance ALS will be cured soon?

There is no cure for ALS currently. Research is ongoing, and new treatments are being developed, but no cure exists. Treatments available today slow progression modestly. It is possible future treatments will be more effective, but there is no timeline for a cure.

If I choose not to use a ventilator, will I suffocate?

When breathing becomes very difficult, palliative care teams provide medications that reduce the sensation of breathlessness and anxiety. The goal is comfort. People who choose not to pursue mechanical ventilation can receive excellent comfort care that makes the end-of-life process less distressing.

Can I still work or live a normal life after an ALS diagnosis?

Early in ALS, many people continue working and living independently. As the disease progresses, work becomes harder and eventually impossible. Adaptations and assistive devices can extend independence. The course depends on how quickly your ALS progresses and what support you have available.